Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 Diabetes

ClinicalTrials.gov ID: NCT00960076

Public ClinicalTrials.gov record NCT00960076. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

18-Week, Multicenter, Randomized, Double-Blind 3b Trial to Evaluate Efficacy/Safety of Saxagliptin in Combo With Metformin XR 1500mg vs Metformin Uptitrated to 2000mg in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control After Diet/Exercise and a Stable Dose of Metformin XR 1500mg

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to compare reduction in A1C for subjects taking Saxagliptin and Metformin XR vs. uptitrated Metformin XR.

Study identification

NCT ID
NCT00960076
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
282 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 78 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2009
Primary completion
Sep 30, 2010
Completion
Sep 30, 2010
Last update posted
Sep 26, 2011

2009 – 2010

United States locations

U.S. sites
22
U.S. states
11
U.S. cities
22
Facility City State ZIP Site status
Research Site Jonesboro Arkansas
Research Site Anaheim California
Research Site Fountain Valley California
Research Site Los Angeles California
Research Site Pasadena California
Research Site Sacramento California
Research Site Gainesville Florida
Research Site Wellington Florida
Research Site Chicago Illinois
Research Site Springfield Illinois
Research Site Indianapolis Indiana
Research Site St Louis Missouri
Research Site Salisbury North Carolina
Research Site Wilmington North Carolina
Research Site Winston-Salem North Carolina
Research Site Columbus Ohio
Research Site Marion Ohio
Research Site Simpsonville South Carolina
Research Site Bristol Tennessee
Research Site Alexandria Virginia
Research Site Burke Virginia
Research Site Manassas Virginia

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00960076, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 26, 2011 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00960076 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →